<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01966458</url>
  </required_header>
  <id_info>
    <org_study_id>HW004-A</org_study_id>
    <nct_id>NCT01966458</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the HeartWare™ Ventricular Assist System (ENDURANCE SUPPLEMENTAL TRIAL)</brief_title>
  <acronym>DT2</acronym>
  <official_title>A Prospective, Randomized, Controlled, Unblinded, Multi-Center Clinical Trial to Evaluate the HeartWare™ Ventricular Assist Device System for Destination Therapy of Advanced Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HeartWare, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HeartWare, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, controlled, unblinded, multi-center evaluation of safety
      and efficacy in patients implanted with a HeartWare® HVAD who receive improved blood pressure
      management. Subjects have chronic Stage D or NYHA Class IIIB/IV left ventricular failure who
      have received and failed optimal medical therapy, and who are ineligible for cardiac
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate non-inferiority of neurologic injury incidence in a new cohort of
      subjects receiving improved blood pressure management to a control group (i.e., any
      FDA-approved LVAD for destination therapy). Secondary endpoints include: a comparison of
      stroke/TIA incidence to a reference observed in the original IDE clinical trial (HW004) that
      did not specify improved blood pressure management; and non-inferiority of stroke-free
      success on the originally implanted device to the control group. Subjects will be randomized
      to HeartWare® HVAD or control LVAD in a 2:1 ratio. Each subject receiving the HeartWare® HVAD
      or control LVAD is followed to the primary and secondary endpoints at 12 months, with a
      subsequent follow-up period extending to 60 months post-implant.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Neurologic Injury</measure>
    <time_frame>Implant to 12 Months</time_frame>
    <description>The primary endpoint is the percent of participants at 12 months on the originally implanted device with neurologic injury, defined as a stroke with Modified Rankin Scale (MRS) &gt; 0 at 24-weeks post-stroke, or a transient ischemic attack (TIA), or a spinal cord infarction (SCI). The Modified Rankin Scale is scored from 0 to 6, where 0 indicates an absence of symptoms and 6 indicates death. A score of 4 or higher indicates moderately severe or greater disability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of HeartWare VAS Participants With Stroke/TIA</measure>
    <time_frame>Implant to 12 Months</time_frame>
    <description>The first secondary endpoint is the number of HeartWare VAS participants with stroke/TIA at 12 months on the originally implanted device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stroke-Free Success</measure>
    <time_frame>Implant to 12 Months</time_frame>
    <description>Success is defined as alive on the originally implanted device, electively transplanted or explanted due to subject recovery and free from disabling stroke (Modified Rankin Scale &gt;=4).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">494</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>HeartWare® VAS (HVAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implant of HeartWare® Ventricular Assist System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control LVAD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implant of FDA-approved LVAD approved for destination therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HeartWare® VAS (HVAD)</intervention_name>
    <description>The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.</description>
    <arm_group_label>HeartWare® VAS (HVAD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control LVAD</intervention_name>
    <description>Any FDA-approved LVAD for destination therapy.</description>
    <arm_group_label>Control LVAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must be ≥18 years of age at consent

          2. Body Surface Area (BSA) ≥ 1.2 m2

          3. Patients with advanced heart failure symptoms (Class IIIB or IV) who are: (patient
             must meet one of the following)a. On optimal medical management, including dietary
             salt restriction and diuretics, for at least 45 out of the last 60 days and are
             failing to respond; or b. In Class III or Class IV heart failure for at least 14 days,
             and dependent on intra-aortic balloon pump (IABP) for 7 days and/or inotropes for at
             least 14 days

          4. Left ventricular ejection fraction ≤ 25%

          5. LVAD implant is intended as destination therapy

          6. Must be able to receive either the HeartWare® HVAD or control LVAD

          7. Patient must agree to participate in and comply with an improved blood pressure
             management program, including maintenance of a patient diary.

          8. Female patients of childbearing potential must agree to use adequate contraceptive
             precautions (defined as oral contraceptives, intrauterine devices, surgical
             contraceptives or a combination of condom and spermicide) for the duration of the
             study.

          9. The patient or legally authorized representative has signed the informed consent form

        Exclusion Criteria:

          1. Body Mass Index (BMI) &gt; 40

          2. Existence of any ongoing mechanical circulatory support (MCS) other than an
             intra-aortic balloon pump (IABP)

          3. Prior cardiac transplant.

          4. History of confirmed, untreated abdominal or thoracic aortic aneurysm &gt; 5 cm.

          5. Cardiothoracic surgery within 30 days of randomization.

          6. Acute myocardial infarction within 14 days of implant as diagnosed by ST or T wave
             changes on the ECG, diagnostic biomarkers, ongoing pain and hemodynamic abnormalities
             as described (Figure 2) in the guidelines published in ACC/AHA 2007 Guidelines for the
             Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction ;.

          7. Patients eligible for cardiac transplantation

          8. On ventilator support for &gt; 72 hours within the four days immediately prior to
             randomization and implant.

          9. Pulmonary embolus within three weeks of randomization as documented by computed
             tomography (CT) scan or nuclear scan.

         10. Symptomatic cerebrovascular disease, stroke within 180 days of randomization or &gt; 80%
             stenosis of carotid or cranial vessels.

         11. Uncorrected moderate to severe aortic insufficiency. Correction may include repair or
             bioprosthesis at the time of implant.

         12. Severe right ventricular failure as defined by the anticipated need for right
             ventricular assist device (RVAD) support or extracorporeal membrane oxygenation (ECMO)
             at the time of screening/randomization or right atrial pressure &gt; 20 mmHg on multiple
             inotropes or right ventricular ejection fraction (RVEF) &lt;15% with clinical signs of
             severe right heart failure (e.g. Lower extremity edema, ascites or pleural effusions
             refractory to treatment with diuretics and two inotropic drugs).

         13. Active, uncontrolled infection diagnosed by a combination of clinical symptoms and
             laboratory testing, including but not limited to, continued positive cultures,
             elevated temperature and white blood cell (WBC) count, hypotension, tachycardia,
             generalized malaise despite appropriate antibiotic, antiviral or antifungal treatment.

         14. Uncorrected thrombocytopenia or generalized coagulopathy (e.g., platelet count &lt;
             75,000, INR &gt; 2.0 or PTT &gt; 2.5 times control in the absence of anticoagulation
             therapy).

         15. Intolerance to anticoagulant or antiplatelet therapies or any other peri- or
             postoperative therapy that the investigator may administer based upon the patient's
             health status.

         16. Serum creatinine &gt; 3.0 mg/dL within 72 hours of randomization or requiring dialysis or
             ultrafiltration.

         17. Specific liver enzymes [AST (SGOT) and ALT (SGPT] &gt; 3 times upper limit of normal
             within 72 hours of randomization.

         18. A total bilirubin &gt; 3 mg/dl within 72 hours of randomization, or biopsy proven liver
             cirrhosis or portal hypertension.

         19. Pulmonary vascular resistance is demonstrated to be unresponsive to pharmacological
             manipulation and the PVR &gt; 6 Wood units.

         20. Patients with a mechanical heart valve.

         21. Etiology of heart failure is due to, or associated with, uncorrected thyroid disease,
             obstructive cardiomyopathy, pericardial disease, amyloidosis, active myocarditis or
             restrictive cardiomyopathy

         22. History of severe COPD or severe restrictive lung disease (e.g. FEV1 &lt;50%)

         23. Participation in any other study involving investigational drugs or devices

         24. Severe illness, other than heart disease, which would limit survival to &lt; 3 years

         25. Peripheral vascular disease with rest pain or ischemic ulcers of the extremities

         26. Pregnancy

         27. Patient unwilling or unable to comply with study requirements

         28. Technical obstacles, which pose an inordinately high surgical risk, in the judgment of
             the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis Pagani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Rogers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic (Arizona)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami / Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Transplant Institute/Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Emory Clinic Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Hospital of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IU Health Methodist</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Ochsner Heart &amp; Vascular Institute</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic / St. Marys Hospital</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University / Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital/Columbia</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundatiojn</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-8802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Heart Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cardiothoracic &amp;Transplant Surgeons</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2013</study_first_submitted>
  <study_first_submitted_qc>October 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2013</study_first_posted>
  <results_first_submitted>February 12, 2018</results_first_submitted>
  <results_first_submitted_qc>March 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 23, 2018</results_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Subjects were considered enrolled upon signing informed consent. 19 enrolled subjects weren't randomized as they were considered screen failures. 10 subjects were randomized but didn't receive a device due to death (with 1 subject dying post anesthesia but prior to Left Ventricular Assist Device (LVAD) implant) or screen failure prior to implant.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HeartWare® Ventricular Assist System (VAS)</title>
          <description>HeartWare® Ventricular Assist System (VAS): The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.</description>
        </group>
        <group group_id="P2">
          <title>Control Left Ventricular Assist Device (LVAD)</title>
          <description>Control Left Ventricular Assist Device (LVAD): Any Food and Drug Administration (FDA)-approved LVAD for destination therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="308"/>
                <participants group_id="P2" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="304"/>
                <participants group_id="P2" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HeartWare® VAS</title>
          <description>HeartWare® VAS: The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.</description>
        </group>
        <group group_id="B2">
          <title>Control LVAD</title>
          <description>Control LVAD: Any FDA-approved LVAD for destination therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="308"/>
            <count group_id="B2" value="157"/>
            <count group_id="B3" value="465"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.3" spread="11.44"/>
                    <measurement group_id="B2" value="64.2" spread="11.14"/>
                    <measurement group_id="B3" value="63.6" spread="11.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="252"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="288"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="442"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>American Indian/Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black/African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian/Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="221"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="339"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Neurologic Injury</title>
        <description>The primary endpoint is the percent of participants at 12 months on the originally implanted device with neurologic injury, defined as a stroke with Modified Rankin Scale (MRS) &gt; 0 at 24-weeks post-stroke, or a transient ischemic attack (TIA), or a spinal cord infarction (SCI). The Modified Rankin Scale is scored from 0 to 6, where 0 indicates an absence of symptoms and 6 indicates death. A score of 4 or higher indicates moderately severe or greater disability.</description>
        <time_frame>Implant to 12 Months</time_frame>
        <population>Subjects were excluded if they withdrew, were lost to follow-up or have missing outcomes on original device.</population>
        <group_list>
          <group group_id="O1">
            <title>HeartWare® VAS</title>
            <description>HeartWare® VAS: The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.</description>
          </group>
          <group group_id="O2">
            <title>Control LVAD</title>
            <description>Control LVAD: Any FDA-approved LVAD for destination therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neurologic Injury</title>
          <description>The primary endpoint is the percent of participants at 12 months on the originally implanted device with neurologic injury, defined as a stroke with Modified Rankin Scale (MRS) &gt; 0 at 24-weeks post-stroke, or a transient ischemic attack (TIA), or a spinal cord infarction (SCI). The Modified Rankin Scale is scored from 0 to 6, where 0 indicates an absence of symptoms and 6 indicates death. A score of 4 or higher indicates moderately severe or greater disability.</description>
          <population>Subjects were excluded if they withdrew, were lost to follow-up or have missing outcomes on original device.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary endpoint is a non-inferiority test comparing HeartWare® VAS to Control.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority margin of 6% was pre-specified.</non_inferiority_desc>
            <p_value>0.1444</p_value>
            <method>Farrington-Manning asymptotic test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>2.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.5</ci_lower_limit>
            <ci_upper_limit>10.7</ci_upper_limit>
            <estimate_desc>Difference = HeartWare® VAS incidence rate - Control incidence rate Two-sided 90% exact binomial confident interval is used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of HeartWare VAS Participants With Stroke/TIA</title>
        <description>The first secondary endpoint is the number of HeartWare VAS participants with stroke/TIA at 12 months on the originally implanted device.</description>
        <time_frame>Implant to 12 Months</time_frame>
        <population>Subjects were excluded if they withdrew or were lost to follow up on the original device.</population>
        <group_list>
          <group group_id="O1">
            <title>HeartWare® VAS</title>
            <description>HeartWare® VAS: The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of HeartWare VAS Participants With Stroke/TIA</title>
          <description>The first secondary endpoint is the number of HeartWare VAS participants with stroke/TIA at 12 months on the originally implanted device.</description>
          <population>Subjects were excluded if they withdrew or were lost to follow up on the original device.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The first secondary endpoint is the percent of participants with stroke/TIA at 12 months on the originally implanted device. It will be compared to 17.7%, which is the lower bound of a pre-defined margin of superiority based on the Endurance clinical trial.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7363</p_value>
            <method>Exact Binomial Test</method>
            <param_type>Percent of Participants</param_type>
            <param_value>19.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.6</ci_lower_limit>
            <ci_upper_limit>23.3</ci_upper_limit>
            <estimate_desc>Two-sided exact binomial confidence interval used</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stroke-Free Success</title>
        <description>Success is defined as alive on the originally implanted device, electively transplanted or explanted due to subject recovery and free from disabling stroke (Modified Rankin Scale &gt;=4).</description>
        <time_frame>Implant to 12 Months</time_frame>
        <population>Subjects were excluded if they had no associated 24 week post-stroke Modified Rankin Scale value, or if the subject withdrew or was lost to follow-up on original device, and no other failure outcome occurred within 1 year post original implant.</population>
        <group_list>
          <group group_id="O1">
            <title>HeartWare® VAS</title>
            <description>HeartWare® VAS: The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.</description>
          </group>
          <group group_id="O2">
            <title>Control LVAD</title>
            <description>Control LVAD: Any FDA-approved LVAD for destination therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stroke-Free Success</title>
          <description>Success is defined as alive on the originally implanted device, electively transplanted or explanted due to subject recovery and free from disabling stroke (Modified Rankin Scale &gt;=4).</description>
          <population>Subjects were excluded if they had no associated 24 week post-stroke Modified Rankin Scale value, or if the subject withdrew or was lost to follow-up on original device, and no other failure outcome occurred within 1 year post original implant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin on the difference in success proportions is 15%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Farrington-Manning asymptotic test</method>
            <param_type>Difference in Percentages</param_type>
            <param_value>-9.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.2</ci_lower_limit>
            <ci_upper_limit>-1.1</ci_upper_limit>
            <estimate_desc>Difference = Control success rate - HeartWare® VAS success rate Two-sided 90% exact binomial confidence interval is used</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0354</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse events are summarized from the date of implant through 12 months while on the originally implanted device. Subjects are analyzed based on the device they actually received.</time_frame>
      <desc>The Intermacs (Interagency Registry for Mechanically Assisted Circulatory Support) adverse event definitions are geared towards subjects who have a mechanically circulatory support device.</desc>
      <group_list>
        <group group_id="E1">
          <title>HeartWare® VAS</title>
          <description>Implant of HeartWare® Ventricular Assist System
HeartWare® VAS: The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.</description>
        </group>
        <group group_id="E2">
          <title>Control LVAD</title>
          <description>Implant of FDA-approved LVAD approved for destination therapy
Control LVAD: Any FDA-approved LVAD for destination therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Intermacs Ver. 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="308"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="295" subjects_at_risk="308"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Major Bleeding</sub_title>
                <counts group_id="E1" events="297" subjects_affected="156" subjects_at_risk="308"/>
                <counts group_id="E2" events="190" subjects_affected="87" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="308"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <counts group_id="E1" events="132" subjects_affected="95" subjects_at_risk="308"/>
                <counts group_id="E2" events="49" subjects_affected="42" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="34" subjects_affected="27" subjects_at_risk="308"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Pericardial Fluid Collection</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="308"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Right Heart Failure</sub_title>
                <counts group_id="E1" events="101" subjects_affected="94" subjects_at_risk="308"/>
                <counts group_id="E2" events="61" subjects_affected="56" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other Intermacs</sub_title>
                <counts group_id="E1" events="599" subjects_affected="219" subjects_at_risk="308"/>
                <counts group_id="E2" events="265" subjects_affected="106" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic Dysfunction</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="308"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Major Infection</sub_title>
                <counts group_id="E1" events="259" subjects_affected="150" subjects_at_risk="308"/>
                <counts group_id="E2" events="149" subjects_affected="85" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological Dysfunction</sub_title>
                <counts group_id="E1" events="83" subjects_affected="57" subjects_at_risk="308"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Malfunction/Failure</sub_title>
                <counts group_id="E1" events="81" subjects_affected="60" subjects_at_risk="308"/>
                <counts group_id="E2" events="46" subjects_affected="38" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric Episode</sub_title>
                <counts group_id="E1" events="35" subjects_affected="34" subjects_at_risk="308"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Dysfunction</sub_title>
                <counts group_id="E1" events="35" subjects_affected="32" subjects_at_risk="308"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="74" subjects_affected="61" subjects_at_risk="308"/>
                <counts group_id="E2" events="37" subjects_affected="31" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Wound Dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Non-CNS Thromboembolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="308"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Venous Thromboembolism</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="308"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Intermacs Ver. 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="308"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="308"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="308"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other Intermacs</sub_title>
                <counts group_id="E1" events="30" subjects_affected="29" subjects_at_risk="308"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Major Infection</sub_title>
                <counts group_id="E1" events="41" subjects_affected="33" subjects_at_risk="308"/>
                <counts group_id="E2" events="32" subjects_affected="24" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Malfunction/Failure</sub_title>
                <counts group_id="E1" events="26" subjects_affected="18" subjects_at_risk="308"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In most cases, the contract allows the principal investigator to publish their data after the release of the multi-center publication (or one year after the conclusion of the study if no multi-center publication is submitted) following the sponsor review for (a) disclosure of confidential information, and (b) information that would impair the sponsor’s ability to obtain patent protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Vassiliades</name_or_title>
      <organization>Medtronic</organization>
      <phone>+15085321942</phone>
      <email>thomas.a.vassiliades@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

